PHARMACOKINETICS OF CEFETAMET (RO-15-8074) AND CEFETAMET PIVOXIL (RO-15-8075) AFTER INTRAVENOUS AND ORAL DOSES IN HUMANS

被引：49

作者：

KOUP, JR

DUBACH, UC

BRANDT, R

WYSS, R

STOECKEL, K

机构：

[1] F HOFFMANN LA ROCHE & CO LTD,DEPT CLIN RES,PHARMACOKINET,CH-4002 BASEL,SWITZERLAND

[2] F HOFFMANN LA ROCHE & CO LTD,DEPT PHARMACEUT RES,PRECLIN DEV,CH-4002 BASEL,SWITZERLAND

[3] UNIV BASEL,HOP CANTONAL,MED OUTPATIENT DEPT,THERAPEUT INVEST STN,CH-4051 BASEL,SWITZERLAND

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 1988年 / 32卷 / 04期

关键词：

D O I：

10.1128/AAC.32.4.573

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

引用

页码：573 / 579

页数：7

共 8 条

[1] CLINICAL PHARMACOKINETICS OF THE 3RD GENERATION CEPHALOSPORINS [J].

BALANT, L ;

DAYER, P ;

AUCKENTHALER, R .

CLINICAL PHARMACOKINETICS, 1985, 10 (02) :101-143

[2] COMPUTATION OF MODEL-INDEPENDENT PHARMACOKINETIC PARAMETERS DURING MULTIPLE DOSING [J].

BAUER, LA ;

GIBALDI, M .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1983, 72 (08) :978-979

[3] NONCOMPARTMENTAL DETERMINATION OF THE STEADY-STATE VOLUME OF DISTRIBUTION [J].

BENET, LZ ;

GALEAZZI, RL .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (08) :1071-1074

[4] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].

COCKCROFT, DW ;

GAULT, MH .

NEPHRON, 1976, 16 (01) :31-41

[5]

Gibaldi M., 1982, PHARMACOKINETICS, P445

[6]

STOECKEL K, 1983, ASIAN PACIFIC C SERI, V19, P5

[7] THE ABSOLUTE BIOAVAILABILITY OF ORAL CEFUROXIME AXETIL IN MALE AND FEMALE VOLUNTEERS AFTER FASTING AND AFTER FOOD [J].

WILLIAMS, PEO ;

HARDING, SM .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1984, 13 (02) :191-196

[8] INVITRO ACTIVITY OF RO 15-8074 AND RO 19-5247, 2 ORALLY-ADMINISTERED CEPHALOSPORIN METABOLITES [J].

WISE, R ;

ANDREWS, JM ;

PIDDOCK, LJV .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 29 (06) :1067-1072

← 1 →